Clinical Research Papers:
Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 3942 views | HTML 4081 views | ?
Abstract
Junwei Tang1,2,*, Runqiu Jiang1,2,*, Lei Deng1,2, Xudong Zhang1,2, Ke Wang1,2, Beicheng Sun1,2
1Liver Transplantation Center of the First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, P.R.China
2Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu Province, P.R.China
*These authors have contributed equally to this work
Correspondence to:
Beicheng Sun, e-mail: [email protected]
Ke Wang, e-mail: [email protected]
Keywords: plasma, lncRNA, microarray, risk score function, ROC curve
Received: November 09, 2014 Accepted: December 16, 2014 Published: February 25, 2015
ABSTRACT
BACKGROUND & AIMS
Alpha Fetal Protein (AFP) was one of the traditional biomarker for diagnosis of Hepatocellular carcinoma (HCC) clinically, however, with the low specificity of AFP, the early diagnosis or the metastasis prediction of HCC is inferior. A new, minimally invasive and more specificity biomarker for the diagnosis or metastasis prediction of HCC are necessary.
METHODS
In this study, we applied an lncRNA microarray to screen the potential biomarker for HCC. The multi-stage validation and risk score formula detection was used for validation.
RESULTS
We discovered three lncRNA, RP11–160H22.5, XLOC_014172 and LOC149086, which were up-regulated in HCC comparing with the cancer-free controls with the merged area under curve (AUC) in training set and validation set of 0.999 and 0.896. Furthermore, XLOC_014172 and LOC149086 was confirmed highly increased in metastasis HCC patients with the merged AUC in training set and validation set of 0.900 and 0.934. Besides, most patients presented a decreased level of the three lncRNAs after operation, while the patients with secondary increased level might be associated with tumor hematogenous metastasis.
CONCLUSIONS
RP11–160H22.5, XLOC_014172 and LOC149086 might be the potential biomarker for the tumorigenesis prediction and XLOC_014172 and LOC149086 for metastasis prediction in the future.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2934